Tenet Healthcare Partners With Commure for Ambient AI Platform

Tenet Healthcare Corporation THC recently partnered with Commure to deploy its AI-driven platform, Commure Scribe, across its employed physician network, Tenet Physician Resources. The ambient AI platform aims to streamline clinical workflows by automating data collection and documentation, reducing administrative tasks for healthcare providers.This move will allow physicians to focus more on patient care, enhancing efficiency and fostering a more patient-centered experience. Tenet Physician Resources employs more than 2,200 physicians and healthcare providers across its national network.Commure, backed by HCA Healthcare, Inc. HCA, General Catalyst and Sequoia Capital, focuses on healthcare AI with a provider- and patient-centric approach to enhance clinical workflows and efficiency. It is expected to reduce providers’ administrative burdens.Healthcare & AITHC actively invests in selected AI-enabled technologies, which are expected to enhance the clinical and administrative workflow and efficiency. This is likely to lower costs, reduce patient wait times, and improve patient experiences. This is a growing trend in the hospital industry, where companies are increasingly adopting AI, automation, and real-time analytics to enhance patient care, streamline workflows, and manage costs.These technologies are helping healthcare providers maintain a competitive edge. This has become the need of the hour as increasing patient volumes and utilization, along with rising costs for supplies, labor and benefits, are pushing hospitals’ operating expenses higher. Hospital companies are also renegotiating supplier contracts to address cost pressures.Tenet Healthcare’s Price PerformanceShares of THC have surged 102.9% in the year-to-date period, outperforming the 22.6% growth of the industry.Image Source: Zacks Investment ResearchTHC’s Zacks Rank & Other Key PicksTenet Healthcare currently sports a Zacks Rank #1 (Strong Buy).Some other top-ranked and promising stocks in the broader Medical sector are CareDx, Inc CDNA and Encompass Health Corporation EHC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for CareDx’s current-year earnings indicates a 162.5% year-over-year improvement. CDNA beat earnings estimates in each of the past four quarters, with an average surprise of 135.2%. The consensus mark for revenues suggests 17.5% growth from the year-ago period.The Zacks Consensus Estimate for Encompass Health’s 2024 full-year earnings implies a 17.6% increase from the year-ago reported figure. EHC beat earnings estimates in each of the last four quarters, with an average surprise of 13.6%. The consensus mark for its current-year revenues is pegged at $5.34 billion, which indicates an 11.2% year-over-year increase.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC): Free Stock Analysis Report HCA Healthcare, Inc. (HCA): Free Stock Analysis Report CareDx, Inc. (CDNA): Free Stock Analysis Report Encompass Health Corporation (EHC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks